Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

NCT06049212 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Solid Tumors
Programmed Cell Death-1 (PD1, PD-1)
Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Interventions

BIOLOGICAL: Sacituzumab tirumotecan
BIOLOGICAL: Pembrolizumab
DRUG: Supportive care measures

Sponsor

Merck Sharp & Dohme LLC